Relative risk reduction is not enough: why cardiorenal trials should routinely report absolute risk reduction and number needed to treat.

Journal: EClinicalMedicine •

Abstract

Abstract text is not embedded in this discovery record. Please consult the full-text publication via the source link on the right.

Subjects & Keywords

How to Cite this Article

Zaitoon H, Abdul-Ghani M, DeFronzo RA (2026). "Relative risk reduction is not enough: why cardiorenal trials should routinely report absolute risk reduction and number needed to treat.". EClinicalMedicine. https://doi.org/10.1016/j.eclinm.2026.104258